BioPharma DiveOriginal article
AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease
Data ReadoutMixedNegative
AI Analysis
Summary
AstraZeneca and Ionis published data in NEJM on silencer medications for TTR cardiomyopathy that raised questions about their benefits beyond standard therapies, creating investor pressure on competitor Alnylam.
Outcome Details
NEJM publication raised questions about benefits of silencer medications on top of standard therapies for TTR cardiomyopathy
Importance:6/10
Sentiment:
-0.40
RNA drugsTTR cardiomyopathyNEJM publicationinvestor pressuresilencer medications
Read the original article
Published by BioPharma Dive on August 28, 2026 2:58 PM